133 related articles for article (PubMed ID: 11076662)
1. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases.
Kruczynski A; Etiévant C; Perrin D; Imbert T; Colpaert F; Hill BT
Br J Cancer; 2000 Dec; 83(11):1516-24. PubMed ID: 11076662
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Barret JM; Kruczynski A; Etiévant C; Hill BT
Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
[TBL] [Abstract][Full Text] [Related]
3. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
4. F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells.
Barret JM; Etiévant C; Baudouin C; Skov K; Charvéron M; Hill BT
Anticancer Res; 2002; 22(1A):187-92. PubMed ID: 12017285
[TBL] [Abstract][Full Text] [Related]
5. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.
Barret JM; Montaudon D; Etiévant C; Perrin D; Kruczynski A; Robert J; Hill BT
Anticancer Res; 2000; 20(6B):4557-62. PubMed ID: 11205304
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity.
Bousquet PF; Braña MF; Conlon D; Fitzgerald KM; Perron D; Cocchiaro C; Miller R; Moran M; George J; Qian XD
Cancer Res; 1995 Mar; 55(5):1176-80. PubMed ID: 7867004
[TBL] [Abstract][Full Text] [Related]
13. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Colpaert F; Tarayre JP; Mouillard P; Fahy J; Hill BT
Cancer Chemother Pharmacol; 1998; 41(6):437-47. PubMed ID: 9554586
[TBL] [Abstract][Full Text] [Related]
14. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
15. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
16. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
19. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
20. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Finch RA; Shyam K; Penketh PG; Sartorelli AC
Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]